Q4 2021 Results
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
Financial performance
Innovation: Pipeline overview
Innovation: Clinical trials
CRM
IHD
Neuroscience
Ophthalmology
Respiratory & Allergy
Oncology: Solid Tumors
Hematology
Biosimilars
Global Health
Abbreviations
tropifexor, licogliflozin - FXR agonist and SGLT 1/2 inhibitor
Study
Indication
Phase
Patients
Primary Outcome
Measures
Arms Intervention
NCT04065841 ELIVATE (CLJN452D12201C)
Non-alcoholic steatohepatitis (NASH)
Phase 2
380
Proportion of patients with resolution of NASH and no worsening of fibrosis OR
improvement in fibrosis by at least one stage without worsening of NASH at Week
48 compared with baseline
Arm A: combination therapytropifexor + licogliflozin
Arm B: tropifexor monotherapytropifexor + licogliflozin placebo
Arm C: licogliflozin monotherapylicogliflozin + tropifexor placebo
Arm D: licogliflozin placebo + tropifexor placebo
Adult patients with biopsy based non-alcoholic steatohepatitis (NASH) and liver
fibrosis
Target Patients
Read-out Milestone(s)
Publication
2023
2023
93 Investor Relations | Q4 2021 Results
NOVARTIS | Reimagining MedicineView entire presentation